Pharmaceutical Technology

JUNE 19, 2023

Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. Laurus Labs will be responsible for launching these products in India and emerging markets.

Gene Therapy 246

Gene Therapy Gene Production Pharma Companies 246

Pharmaceutical Technology

APRIL 22, 2024

Develop a stable cell line for high-titer rAAV production with Ultragenyx's patented method involving HDAC inhibitors and AAV rep proteins. Explore the groundbreaking patent now!

Development 130

Development Protein Production 130

Camargo

JUNE 3, 2020

The post Patient-Centered Drug Development for Oncology Products appeared first on Camargo. Oncology patients face a difficult journey — a frightening diagnosis followed by intricate and oftentimes.

Production 130

Production Development Drugs 130

Pharmaceutical Technology

SEPTEMBER 22, 2023

JURA Bio has entered into a research collaboration with Replay cell therapy product company Syena for the development of TCR based therapies.

Development 246

Development Production Research 246

Pharmaceutical Technology

NOVEMBER 1, 2022

FEATURED COMPANIES COMMENDED : • Innovation • Product Launch • Safety VIEW PROFILE COMMENDED : • Business Expansion • Innovation • Investments VIEW PROFILE COMMENDED: • Social VIEW PROFILE. What is Research and Development (R&D)? This category highlights companies that have advanced drug development research.

Development 228

Development Research Production Vaccination 228

Pharmaceutical Technology

MAY 23, 2023

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. The plentiful supply of QS-21 enables the production of next-generation adjuvant systems for new vaccine development.”

Production 240

Production Vaccination Vaccine Life Science 240

Pharma Mirror

FEBRUARY 6, 2024

By Barbara Arone, Vice President, Real World Solutions, IQVIA The use of real-world evidence (RWE) in the development of pharmaceutical treatments has grown exponentially in the past 10 years, fueled by availability of higher quality data, trial competitiveness and growing investments in personalized and rare disease treatments.

Production 100

Production Packaging Packaging Clinical Research 100

Camargo

OCTOBER 15, 2020

If a single-arm trial was conducted as the pivotal trial for regulatory approval of those existing products, the sponsor will certainly want to do the same. Similarly, in rare disease drug development, where a placebo control group may not be an option, a single-arm trial can be a successful approach.

Production 190

Production Trials Development Clinical Trials 190

Pharmaceutical Technology

MAY 9, 2023

Ginkgo Bioworks and Boehringer Ingelheim have collaborated to develop breakthrough therapies for hard-to-treat diseases. The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Development 261

Development Sales Protein Production 261

Pharma Mirror

JANUARY 24, 2023

Science-based innovation for manufacturing high quality cells challenges dogma and terminology Cell and gene therapies are dominating the world of drug development. billion by 2026, up from $186 billion in 2019 according to the Evaluate Pharma report.

Production 130

Production Gene Therapy Manufacturing Gene 130

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). Astellas and Sutro will expedite the development of iADCs for three different biological targets. It can potentially enhance the anti-cancer effect.

Development 264

Development Antibody Immune Response Production 264

Camargo

MAY 19, 2020

The post What to Expect from the FDA During COVID-19 Product Development appeared first on Camargo. As the COVID-19 national emergency stretches on in the United States, the eyes of the.

Production 140

Production Development 140

Fierce Pharma

APRIL 25, 2024

Where innovation meets obstacles and the cost of drug development skyrockets, the key to unlocking success of groundbreaking products in the biopharma industry will rely heavily on strategic | Collaborative partnerships key to clearing the path for new biopharma products

Production 68

Production Development Drugs 68

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Pharma Times

APRIL 16, 2024

Solid organ transplantation is used to treat end-stage organ failure, including the kidneys

Production 135

Production Development 135

Pharmaceutical Technology

MARCH 29, 2023

Regeneron Pharmaceuticals has collaborated with Sonoma Biotherapeutics to discover, develop and commercialise new regulatory T cell (Treg) therapies for autoimmune diseases. The two companies will together research and develop T cell therapies for Crohn’s disease and ulcerative colitis, as well as two other undisclosed indications.

Development 245

Development Gene Therapy Gene Production 245

Pharmaceutical Technology

MARCH 21, 2023

Pre-clinical-stage biotechnology firm InvisiShield Technologies has partnered with Gladstone Institutes to develop intranasal preventatives against airborne viral infections including influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. Tests of live virus can take place in its advanced Biosafety Level 3 (BSL-3) facility.

Development 288

Development Scientist Vaccination Vaccine 288

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Kite will carry out the manufacturing following the technical transfer.

Development 264

Development Gene Therapy Clinical Trials Clinical Trials 264

Bio Pharma Dive

MAY 19, 2021

A number of drugmakers have recently faced development delays after the FDA's asked for more information on how they measure the potency of their products.

Gene Therapy 362

Gene Therapy Development Gene Production 362

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 3, 2023

Indian medical devices companies are increasingly looking to invest in innovation for developing products that help to minimize environmental footprint.

Production 149

Production Genome Genomics Development 149

Pharmaceutical Technology

APRIL 5, 2023

Austrian molecular glue degraders discovery and development company Proxygen and Merck , known as MSD outside the US and Canada, have entered into a multi-year research collaboration and licence deal. Proxygen will receive royalties on net sales of products developed under the partnership.

Development 246

Development Engineer Sales Research 246

World of DTC Marketing

APRIL 5, 2022

The old model of looking at performance in the first six months of product launch isn’t relevant. Today, colossal budget product launches are not returning the same ROI as before. Product launches are going to need to be micro-targeted to specific audiences. What is the definition of a successful pharma product launch?

Production 196

Production Pharma Companies Branding Marketing 196

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. The collaboration will help in further development of BB-1701 across the world and advance the ADC towards late stage of development.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. However, following its launch of the world’s first Omicron BA.4/BA.5

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

Scienmag

MAY 17, 2022

Well known for their applications in the production of therapeutic proteins like insulin, plasmids are broadly used in the large-scale production of many bioproducts. These small, circular DNA molecules are used by scientists to introduce new genes into a target organism. Credit: CABBI Plasmids have extensive […].

Production 90

Production Insulin Development DNA 90

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Development 264

Development Hormones Production Marketing 264

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development 246

Development Protein RNA Genetics 246

Pharmaceutical Technology

NOVEMBER 16, 2022

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Pharmaceutical Technology

OCTOBER 3, 2023

Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers.

Production 130

Production Clinical Development Development 130

Pharmaceutical Technology

OCTOBER 3, 2023

Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers.

Production 130

Production Clinical Development Development 130

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies.

Vaccination 245

Vaccination Vaccine Development Allergies 245

Drug Patent Watch

OCTOBER 12, 2021

International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Md.

Generic Drugs 105

Generic Drugs Production Development Drugs 105

Pharmaceutical Technology

DECEMBER 5, 2022

Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. TherapeuticsMD will also sell specific assets to Mayne, permitting the latter to market these products, including inventory. Additionally, TherapeuticsMD is entitled to receive another nearly $13.1m

Licensing 130

Licensing Licensing Production Marketing 130

Fierce Pharma

FEBRUARY 20, 2024

After laying out plans to absorb a pair of production subsidiaries in October, Japan’s Daiichi Sankyo is doubling down on its quest to dominate the red-hot antibody-drug conjugate (ADC) field. Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08

Antibody 106

Antibody Production Drugs Manufacturing 106

BioPharma Reporter

APRIL 17, 2024

BSI, sat down with Liza Laws, the senior editor of OSP and BPR to discuss his companyâs pioneering work in revolutionizing vaccine adjuvant production. During DCAT this year, Gaston Saperi from Botanical Solutions Inc.,

Production 95

Production Vaccination Vaccine Clinical Development 95

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.

Development 241

Development RNA Gene Therapy Genetics 241